Clearstead Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Clearstead Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4	Closed	-$41	–	3201
2025 Q2	$41	Buy	+4	New	+$27	﹤0.01%	2683

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Clearstead Advisors's ORIC Position: Q3 2025 in Review

Clearstead Advisors sold out of Oric Pharmaceuticals (ORIC) in Q3 2025, closing a stake of 4 shares — an estimated $41 sold.

Clearstead Advisors first reported a position in ORIC in Q2 2025 and held it in 1 quarter. The position peaked at $41 in Q2 2025. 152 funds tracked by Wall St. Rank hold ORIC as of Q3 2025.

Clearstead Advisors reported no remaining Oric Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Clearstead Advisors sold 4 Oric Pharmaceuticals shares in Q3 2025, an estimated $41.
Clearstead Advisors first reported a position in Oric Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Clearstead Advisors's Oric Pharmaceuticals position peaked at $41 in Q2 2025.
152 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.